The Welsh Government has today confirmed £16m to extend the New Treatment Fund in Wales.
The ABPI has commented in response to calls for intellectual property rights to be waived in relation to COVID-19.
The Government has laid a statement in Parliament updating on the Independent Medicines and Medical Devices Safety Review by Baroness Cumberlege.
The Department of Health and Social Care has published the UK Rare Diseases Framework today, a national vision of how the UK will improve the lives of those living with rare diseases.
Earlier this week the British Medical Journal (BMJ) published and publicised a story which we believe inaccurately depicts the work of the pharmaceutical industry in the UK. Our chief executive Mike Thompson has written a letter to the BMJ in response.
The Association of the British Pharmaceutical Industry (ABPI) - representing leading global pharmaceutical businesses in the UK - have welcomed the EU Council's agreement to progress Brexit negotiations to the next phase and the EU Council's approval of a transition period.
Last week, the EMA announced it has completed the reallocation of the medicines for which the UK's national regulator - the MHRA - is currently rapporteur or co-rapporteur appointed by the scientific committees to coordinate the evaluation of a medicine.
Following a consultation, the Government has today announced changes to the Human Medicines Regulations, which will support the rollout of any COVID-19 vaccine.
The AMRC and more than 30 top pharmaceutical and health tech companies have signed an open letter to the Prime Minister urging Government to provide financial support for medical research charities.
This week the Health Research Authority and National Institute for Health Research jointly published a report of the general public's attitudes towards health research.
